Vitroscope Raises $7 Million for Organoid Platform
The Norwegian startup's seed round and non-dilutive funding will support commercial rollout of its perfusion platform for living tissue models.
Updated on Nov. 3, 2026 in Biotech
Vitroscope has raised $7 million, comprising a $5 million seed round co-led by Cerberus Ventures and YZR Capital and $2 million in non-dilutive funding from the Research Council of Norway. The company has now raised $8.8 million to date.
Why it matters
Static well plates cannot replicate the flow and oxygen conditions that organoids and fresh human tissue models require, which limits the reliability of lab research. The funding will support the commercial rollout of vitro.alive and validation of the larger vitro.scale system.
The vitro.alive benchtop platform combines programmable perfusion with real-time control of oxygen, pH and temperature and supports six independent, parallel experiments. The planned vitro.scale system is designed for 96 parallel experiments, though it remains in development and its performance has not yet been independently verified.
The players
Vitroscope
A Norwegian biotechnology company developing automated perfusion platforms for living human tissue models, holding multiple international patents on its core technology.
Cerberus Ventures
A venture capital firm that co-led the $5 million seed round in Vitroscope.
YZR Capital
A venture capital firm that co-led the $5 million seed round in Vitroscope.
Research Council of Norway
Norway's national public agency for research funding, which provided the $2 million in non-dilutive funding to Vitroscope.
The details
Vitroscope's automated perfusion platform maintains controlled flow through living tissue and works with standard inverted microscopes, allowing researchers to keep their existing tissue models. In collaboration with Instant Bio, the company kept vascularised human brain organoids under perfusion for seven days using vitro.alive.
Timeline
2027: Customer testing of vitro.scale is expected to begin.
2028: vitro.scale has a planned launch.
The Tech Race
Organoid research has long relied on static well plates, which cannot deliver the flow and oxygen that living tissue requires. Vitroscope's perfusion platform represents an alternative approach aimed at replacing that legacy setup in laboratories that already use inverted microscopes.
Researchers using organoids or fresh human tissue models could eventually keep their existing microscopes while gaining controlled flow and oxygen for longer experiments. The benchtop format is designed to fit into current lab workflows without requiring new equipment beyond the perfusion platform itself.
The takeaway
Better control of living tissue conditions may make organoid experiments more reproducible, which could matter for drug testing and disease research. Readers following lab technology should watch for independent validation as vitro.scale approaches customer testing.
What happens next
Customer testing of vitro.scale is expected to begin in 2027, with a planned launch in 2028.
Further reading
For related developments in lab research tools, see the Biotech section.
Source note: This article includes information reported by Tech.
